Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
REDWOOD CITY, Calif., March 01, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.
- A company presentation is scheduled at the 37th Cowen & Co. Healthcare Conference on Monday, March 6th at 4:40 p.m. ET taking place in Boston, MA.
- A company presentation is scheduled at the Barclays Global Healthcare Conference on Wednesday, March 15th at 9:30 a.m. ET taking place in Miami, FL.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O'Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
